20 September 2021

Jena/Germany | Dublin/USA | Carl Zeiss Meditec AG

At ZEISS Innovation Week, September 21-23, 2021, ZEISS Medical Technology will introduce industry-first, integrated solutions that bring further value to the ZEISS Medical Ecosystem, connecting devices, data and applications that will help maximize clinical efficiency and performance.

“ZEISS continues to invest in digital technologies, bringing our digital offerings to the next level with the ZEISS Medical Ecosystem which helps customers leverage the value of a connected environment,” said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “It is our mission to contribute to the progress of medicine, enabling more efficient and cost-effective treatments and providing access to high-quality medical care to as many people as possible. Our investment in digital technology will continue to make adoption of digitalization easy and intuitive.”

ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the
ZEISS QUATERA 7001. This revolution in phaco technology includes the ZEISS patented QUATTRO Pump® which delivers chamber stability independent of intra-ocular pressure (IOP) and flow. The QUATERA 700 increases a surgeon’s workflow efficiency from the clinic to the operating room, enabling one digitally integrated surgical workflow. “I have been looking forward to having this system in my OR, it was a big moment for me,” said Sri Ganesh, MD, Chairman and Managing Director of Nethradhama Super Speciality Eye Hospital, Bangalore/India. “Then I saw that it actually works - the chamber is so stable, the new pump works very well. It is something that I’ve never seen before and I’ve used all different phaco machines in my career of almost three decades.”

The ZEISS Cataract Workflow is further enhanced with two new and original surgical software applications. The new ZEISS EYEGUIDE1 patient software application is a virtual coach for patients and clinics to stay connected through the entire cataract treatment process. The ZEISS Surgery Optimizer1 application is developed for surgeons as a new and innovative way of utilizing surgical videos to enable self-training of physicians and standardization of surgical techniques.

Additionally, the new ZEISS CT LUCIA 6211 monofocal IOL features the patented ZEISS Optic (ZO) Asphericity Concept with its uniquely forgiving design to deliver excellent visual outcomes for a broad range of patients and surgical situations, and the new ZEISS OPTIKIT1 offers a fully customizable surgical pack that perfectly complements the ZEISS Lens Extraction offering.

“Together with ZEISS’ data platform and surgical planning software, these innovations position ZEISS as a full surgical leader in ophthalmology,” said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec. “Harnessing the power of data-generated insights ZEISS creates an environment where connectivity, automation, artificial intelligence, and safe and efficient management of data can solve the challenges that customers face every day.”

The new ZEISS VISUMAX 8001, the next generation of ZEISS femtosecond lasers, creates a comfortable patient and surgeon experience by reducing laser time and potential transcription errors with easy treatment planning and data analysis via FORUM® to the ZEISS Refractive Workplace1 through a digitally connected corneal refractive workflow.

“I am sure every surgeon will appreciate the benefits that come with the digital connectivity such as elimination of transcription errors and the possibility of remote planning, but really the greatest step forward is the incredible speed of the VISUMAX 800 laser scanning making suction loss virtually a thing of the past,” said Prof. Dr. Walter Sekundo, Professor and Chairman, Ophthalmology Department, Philipps University of Marburg, Germany.

Additionally, the ZEISS Retina Workflow has been enhanced beyond the traditional ophthalmology office and into primary healthcare settings with the new ZEISS VELARA Teleretinal Screening System, a complete end-to-end solution used by primary care providers to help increase the quality and compliance of diabetic patients, allowing annual retinal exams to be completed during routine primary care visits. The solution is available only in the U.S. initially.

“We always think of ourselves as providing the best medical care available. And so how can we do that in the shortest time possible, how can we get patients in and out?” said Dr. Nathan Kiskila, Urgent Care General Practitioner President, Founder and Co-Owner of Marque Medical, California/USA. “The ZEISS VELARA Teleretinal Screening System is one more thing that I think we will have in our toolbox as physicians to offer to our patients to really provide good medical care and make things happen.”

The new integrated devices, software applications and other workflow solutions will be showcased this week during the ZEISS Innovation Week from September 21 to 23, 2021. For more information, visit www.zeiss.com/med.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med


Share this article

  • 1

    ZEISS QUATERA 700, ZEISS CT LUCIA 621, ZEISS Surgery Optimizer, ZEISS EYEGUIDE, ZEISS OPTIKIT, ZEISS VISUMAX 800 and ZEISS Refractive Workplace are not available for sale or use in some markets.